Anixa Biosciences (NASDAQ:ANIX) has commercially launched Cchek Prostate Cancer Confirmation test (Cchek PCC), the first test developed with the Cchek artificial intelligence driven, flow cytometry based, liquid biopsy technology platform.
This test is designed to confirm the need for prostate biopsy, as a means to minimize unnecessary invasive procedures and reduce healthcare costs associated with traditional methods of prostate cancer diagnosis and the associated adverse events.
The Company expects Cchek PCC to be broadly available throughout the U.S. by April 2020.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.